Toronto, Ontario--(Newsfile Corp. - September 23, 2025) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce its participation at the upcoming 2025 Cantech Investment Conference on Thursday, October 9, 2025 in Toronto, Ontario. HEALWELL will be represented at the Cantech Investment Conference by Dr. Alexander Dobranowski, President, and Anthony Lam, CFO, who will deliver an investor presentation and participate in scheduled 1-on-1 meetings with investors.
Presentation Time: 2:00 PM EST in Track 1
Date: Thursday, October 9, 2025
Location: Arcadian Loft, 8th floor, 401 Bay Street, Toronto, ON
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. to register
More info: https://www.cantechletter.com/conference/
Dr. Alexander Dobranowski will also be speaking on the Lunch Keynote Panel: "AI Investment Opportunities", where he will share HEALWELL's capital allocation story and highlight the Company's growth over the past two years.
Dr. Alexander Dobranowski, President of HEALWELL, commented, "We are pleased to be presenting at the Cantech Investment Conference again this year. Cantech brings together Canada's leading investors, analysts, and capital markets professionals. The conference provides an excellent opportunity to share HEALWELL's vision for advancing preventative healthcare through AI and to further engage with the investment community."
James Lee
Chief Executive Officer
HEALWELL AI Inc.
About The Cantech Investment Conference
The Cantech Investment Conference, recognized as Canada's foremost technology and diversified industries investment event, provides emerging companies with the unique opportunity to showcase their innovations and growth strategies, and participate in individual 1-on-1 meetings with potential investors and capital markets professionals. The conference serves as a hub for networking, knowledge exchange, and investment opportunities, while also featuring panel discussions with industry experts to offer insights into current trends, challenges, and opportunities. For fifteen years, Cantech Media, the parent company of Cantech Letter, has been committed to the innovation sectors in the Canadian public markets. Cantech Letter gathers research from Canada's leading investment banks to provide individual investors with timely, expert voices in the space.
About HEALWELL AI
HEALWELL is a healthcare artificial intelligence company focused on preventative care. Its mission is to improve healthcare and save lives through early identification and detection of disease. Using its own proprietary technology, the Company is developing and commercializing advanced clinical decision support systems that can help healthcare providers detect rare and chronic diseases, improve efficiency of their practice and ultimately help improve patient health outcomes. HEALWELL is executing a strategy centered around developing and acquiring technology and clinical sciences capabilities that complement the Company's road map. HEALWELL is publicly traded on the Toronto Stock Exchange under the symbol "AIDX" and on the OTC Exchange under the symbol "HWAIF". To learn more about HEALWELL, please visit https://healwell.ai/.
For more information:
Pardeep S. Sangha
Investor Relations, HEALWELL AI Inc.
Phone: 604-572-6392
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | C$1.57 |
Daily Change: | 0.05 3.29 |
Daily Volume: | 580,320 |
Market Cap: | C$417.210M |
September 25, 2025 September 18, 2025 August 13, 2025 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load